Evaluation of the efficacy of Maa-al-shaeer (product based on barley seeds) on radiotherapy induced dysuria

Evaluation of efficacy of Maa-al-shaeer (An Iranian medicine product based on barley seeds) in preventing and reducing the severity of radiotherapy-induced dysuria in prostate cancer patients; a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190608043840N1

Enrollment

Registered

2023-01-22

Start date

2023-02-01

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer, Radiotherapy-induced dysuria, Urogenital radiotherapy complications. C61

Interventions

Intervention 1: Intervention group: Twice a day, every 12 hours, one measure of "Maa-al-shaeer" (malted barley powder which was prepared by the school of Traditional Medicine of Shahid Beheshti Univer

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Over 18 years old Prostate cancer Candidate for radiation therapy (at the Radiotherapy Center of Shohada-e-Tajrish Hospital) Consciousness

Exclusion criteria

Exclusion criteria: Unconsciousness or unable to report dysuria Urinary catheter Urinary tract infection Diabetes Mellitus Dysuria A history of drug sensitivity Metastasis Chemotherapy at the same time Hematuria Severe Cardiovascular, Pulmonary, Hepatic and Kidney diseases that need some medical treatments Not participating in the study

Design outcomes

Primary

Measure	Time frame
Dysuria. Timepoint: Before intervention and 2, 4, 6, 8 weeks after intervention. Method of measurement: IPSS (International prostate symptom score) questionnaire.	—

Secondary

Measure	Time frame
Quality of Life. Timepoint: Quality of life score before the intervention (week 0) 4 and 8 weeks after the intervention. Method of measurement: EORTC QLQ-PR25 Questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Prostate Cancer).;The number of phenazopyridine tablets which was used. Timepoint: 2, 4, 6 and 8 weeks after the intervention. Method of measurement: Asking the participants.;Treatment satisfaction. Timepoint: 8 weeks after the intervention. Method of measurement: It is measured by asking 1 Likert scale question (very high, high, medium, low and very low).	—

Measure

Time frame

Quality of Life. Timepoint: Quality of life score before the intervention (week 0) 4 and 8 weeks after the intervention. Method of measurement: EORTC QLQ-PR25 Questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Prostate Cancer).;The number of phenazopyridine tablets which was used. Timepoint: 2, 4, 6 and 8 weeks after the intervention. Method of measurement: Asking the participants.;Treatment satisfaction. Timepoint: 8 weeks after the intervention. Method of measurement: It is measured by asking 1 Likert scale question (very high, high, medium, low and very low).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVida Nazari

Shahid Beheshti University of Medical Sciences

vidanazary@sbmu.ac.ir+98 21 8877 3521

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026